Aikium Inc., founded in Berkeley, California, is a pre-seed startup specializing in protein therapeutics. Their core mission is to revolutionize treatments for neuro-inflammation and oncology through innovative synthetic biology and deep learning technologies. Aikium's flagship product, the SeqR protein, is a non-antibody scaffold designed for precise programmable binding with universal target coverage, addressing multi-pass membrane protein targets that traditional antibody-based approaches cannot reach.
Aikium operates out of the Bakar Bioengenuity Hub and has developed its proprietary AI platform, Yotta-ML², to enhance its therapeutic solutions. The company has attracted attention for its cutting-edge approach and potential impact on the biotechnology field. While specific investors and affiliated notable individuals are not disclosed, Aikium's advancements in synthetic biology and deep learning mark significant strides in protein therapeutics, positioning it as a promising player in the biotech industry.
